Shire Aims for Market Leadership in Rare Diseases with US$32 B Baxalta Acquisition

By Heather Cartwright, Rohit Khera & Jasmine Kalsi

Pharma Deals Review: Vol 2016 Issue 1 (Table of Contents)

Published: 27 Jan-2016

DOI: 10.3833/pdr.v2016.i1.2140     ISSN: 1756-7874

Section: Mergers & Acquisitions



Shire has emerged victorious in its 6-month quest to acquire haemophilia specialist Baxalta with a cash-plus-stock deal worth approximately US$32 B...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details